Halozyme Therapeutics, Inc. (HALO) Downgraded to “Neutral” at Citigroup Inc.

Citigroup Inc. lowered shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) from a buy rating to a neutral rating in a research report released on Friday.

Several other research analysts have also issued reports on HALO. Jefferies Group restated a sell rating and set a $6.75 target price on shares of Halozyme Therapeutics in a research report on Tuesday, November 8th. Deutsche Bank AG initiated coverage on Halozyme Therapeutics in a research report on Thursday, November 3rd. They set a buy rating and a $12.00 target price for the company. Piper Jaffray Companies boosted their target price on Halozyme Therapeutics from $15.00 to $18.00 and gave the company an overweight rating in a research report on Friday, September 16th. Finally, Wells Fargo & Company restated a buy rating on shares of Halozyme Therapeutics in a research report on Thursday, September 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. Halozyme Therapeutics currently has a consensus rating of Buy and a consensus price target of $13.96.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ:HALO) traded up 6.43% on Friday, reaching $14.24. The company had a trading volume of 4,140,358 shares. Halozyme Therapeutics has a 52 week low of $6.96 and a 52 week high of $15.44. The company’s market capitalization is $1.82 billion. The stock’s 50-day moving average is $11.44 and its 200-day moving average is $10.49.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.04. Halozyme Therapeutics had a negative return on equity of 405.28% and a negative net margin of 44.60%. The company had revenue of $31.90 million for the quarter, compared to analysts’ expectations of $34.43 million. During the same period in the previous year, the firm posted ($0.19) earnings per share. The firm’s revenue for the quarter was up 53.4% on a year-over-year basis. Equities research analysts forecast that Halozyme Therapeutics will post ($0.87) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be read at https://www.com-unik.info/2017/01/09/halozyme-therapeutics-inc-halo-downgraded-to-neutral-at-citigroup-inc.html.

A number of hedge funds have recently bought and sold shares of HALO. Commonwealth Equity Services Inc bought a new stake in Halozyme Therapeutics during the second quarter worth $109,000. BNP Paribas Arbitrage SA raised its stake in Halozyme Therapeutics by 113.7% in the third quarter. BNP Paribas Arbitrage SA now owns 9,051 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 4,815 shares in the last quarter. Amalgamated Bank raised its stake in Halozyme Therapeutics by 3.0% in the second quarter. Amalgamated Bank now owns 11,518 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 338 shares in the last quarter. Royal Bank of Canada raised its stake in Halozyme Therapeutics by 13.5% in the second quarter. Royal Bank of Canada now owns 14,200 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 1,685 shares in the last quarter. Finally, Parametrica Management Ltd bought a new stake in Halozyme Therapeutics during the third quarter worth $131,000. Institutional investors own 81.10% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.

5 Day Chart for NASDAQ:HALO

What are top analysts saying about Halozyme Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Halozyme Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit